# **The Neuroimmunological Application of Peptide Bioregulators in the Treatment of Chronic Infection-Induced Anhedonia**

The clinical convergence of chronic infectious states and the profound neuropsychiatric symptom of anhedonia represents a significant challenge for modern medicine, necessitating a paradigm shift from traditional monoaminergic psychiatry toward a more integrated neuroimmunological framework. Anhedonia, defined as the diminished capacity to experience pleasure or interest in rewarding stimuli, is no longer viewed solely as a psychological manifestation of mood disorders but as a direct, quantifiable consequence of systemic immune activation on the central nervous system reward circuitry.1 Specifically, the persistent release of pro-inflammatory cytokines during chronic infection acts as a physiological wedge that disrupts the synthesis, release, and reuptake of dopamine within the basal ganglia and the ventral striatum.1

In evaluating the provided therapeutic options, the series of peptide complexes (PC 01 through PC 19\) developed by the St. Petersburg Institute of Bioregulation and Gerontology under the guidance of Vladimir Khavinson offers a unique epigenetic approach to reversing these pathological states.5 These short-chain peptides, often referred to as bioregulators, are designed to penetrate the cell nucleus and interact directly with DNA sequences and histone proteins to restore tissue-specific protein synthesis that has been suppressed by chronic stress or infection.7 To determine the optimal treatment strategy among these complexes, it is essential to first dissect the molecular mechanisms by which chronic infection induces anhedonia and then map those mechanisms to the specific regulatory targets of the peptide complexes.

## **The Pathophysiology of Inflammation-Mediated Dopamine Dysfunction**

The link between chronic infection and anhedonia is primarily mediated by the immune-to-brain signaling axis, where systemic inflammatory markers penetrate the blood-brain barrier or signal through the vagus nerve to alter the neurochemical landscape of the subcortical brain regions.1 Data suggest that cytokines released during the inflammatory response target subcortical structures including the basal ganglia as well as dopamine function to acutely induce behavioral changes that support fighting infection and wound healing.1 However, when an infection becomes chronic, the persisting alterations in the basal ganglia and dopamine function manifest as persisting anhedonia, fatigue, and psychomotor slowing.1

The neurobiological "hit" on the dopamine system occurs at multiple metabolic intersections. Chronic exposure to inflammatory cytokines such as interferon-alpha (![][image1]), interleukin-6 (![][image2]), and tumor necrosis factor-alpha (![][image3]) has been shown to reduce neural responses to hedonic reward and decrease dopamine metabolites in the cerebrospinal fluid.1 One critical pathway involves the depletion of tetrahydrobiopterin (![][image4]), which serves as an essential co-factor for tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of dopamine.1 Furthermore, inflammatory signals stimulate the enzyme indoleamine 2,3-dioxygenase (IDO), which shunts the metabolism of tryptophan away from serotonin and toward the kynurenine pathway, resulting in the production of neurotoxic metabolites like quinolinic acid that further impair dopaminergic neurons in the ventral striatum.2

| Cytokine Mediator | Primary Neurological Target | Impact on Reward Circuitry |
| :---- | :---- | :---- |
| **![][image1]** | Basal Ganglia / Ventral Striatum | Reduced DA synthesis; decreased reward sensitivity 1 |
| ![][image3] | Dopamine Transporter (DAT) | Increased presynaptic DA uptake; reduced synaptic availability 1 |
| ![][image2] | Mesolimbic Neurocircuits | Disruption of DA turnover; context-dependent mood instability 4 |
| Quinolinic Acid | NMDA Receptors / Striatum | Oxidative stress; glutamate-mediated neurotoxicity 2 |

The multiplicity of these changes—encompassing dopamine synthesis, packaging, release, and reuptake—suggests that inflammatory cytokines act as a fundamental sabotage of current treatment approaches like Selective Serotonin Reuptake Inhibitors (SSRIs), which may explain why a significant proportion of "inflammatory subtype" depressed patients fail to respond to standard care.1

## **The Khavinson Peptide Bioregulator Paradigm**

The discovery of peptide bioregulators originated from a classified Soviet research program intended to bolster the resilience of military personnel against extreme stressors, including radiation, biological toxins, and chronic infectious diseases.5 These bioregulators are organ-specific di-, tri-, and tetrapeptides that act as signaling molecules capable of interacting with DNA and histone proteins.9 Unlike conventional peptides that may work through cell surface receptors, these bioregulators cross the gut barrier and the blood-brain barrier, entering cell nuclei to bind to regulatory regions of the genome.7

The mechanism of action for these peptides involves the restoration of the "protein-peptide cycle," where short peptides act as molecular "keys" that unlock specific genetic programs.7 In the context of chronic illness, genes responsible for cellular repair and immune defense may be silenced or repressed by epigenetic factors such as DNA methylation or histone deacetylation.7 Specific peptides, such as the tetrapeptide Ala-Glu-Asp-Gly (Epitalon), have been shown to bind to histones H1/3 and H1/6, which are critical for chromatin condensation, thereby facilitating the transcription of genes involved in neurogenesis and cellular restoration.8

| Peptide Name | Sequence | Origin Organ | Primary Bioregulatory Effect |
| :---- | :---- | :---- | :---- |
| Epitalon | Ala-Glu-Asp-Gly | Pineal Gland | Melatonin restoration; neurogenesis; telomere elongation 5 |
| Thymalin | Polypeptide Complex | Thymus Gland | T-cell differentiation; cytokine regulation 5 |
| Cortexin | Polypeptide Complex | Cerebral Cortex | Neuronal metabolism; synaptic plasticity; cognitive support 5 |
| Vilon | Lys-Glu | Synthetic/Thymus | Immunostimulation; fibroblast activation 13 |
| Thymogen | Glu-Trp | Synthetic/Thymus | Immune modulation; infection resolution 6 |

These bioregulators possess an exceptional safety profile, as they are bio-identical to the peptides naturally produced in the human body, lacking toxic or allergic effects even after long-term administration.5 Their ability to work at nanomolar concentrations makes them a highly efficient tool for addressing the underlying dysregulation of cellular communication in chronic illness.7

## **Systematic Review of Peptide Complexes 01–19 in the Context of Anhedonia**

To address the specific requirement of identifying the best treatment for chronic infection-induced anhedonia, an analysis of the target systems for each liquid peptide complex (PC) is necessary. These liquid complexes are typically applied transdermally to the inner forearm, entering the lymphatic system and eventually the systemic circulation.13

### **Peptide Complex 03: The Etiological Intervention (Immune System)**

Peptide Complex 03 targets the immune system and is fundamentally comprised of thymic peptides similar to Thymalin or Thymogen.14 In the context of chronic infection, the immune system often enters a state of exhaustion or chronic over-activation (low-grade inflammation) that is the primary source of the cytokines driving anhedonia.7 By restoring natural killer (NK) cell function and rebalancing the Th1/Th2 immune response, PC 03 facilitates the clearance of the underlying pathogen while simultaneously dampening the pro-inflammatory signaling that inhibits the dopamine system.7 This makes PC 03 the "best" choice for treating the *root cause* of the anhedonic state.

### **Peptide Complex 021: The Symptomatic Intervention (Nervous System)**

Peptide Complex 021 (which corresponds to the central and peripheral nervous system complex) is the primary candidate for addressing the *neurological seat* of anhedonia.17 This complex contains brain-derived peptides, likely related to the A-5 complex (Cerluten), which have been shown to improve memory, concentration, and emotional stability.15 In cases of anhedonia, PC 021 targets the subcortical structures like the basal ganglia, promoting the repair of neurons damaged by neuroinflammation and enhancing synaptic plasticity.1 This complex is essential for "re-awakening" the reward circuitry once the primary infection is under control.

### **Peptide Complex 01: Microcirculatory Support**

Peptide Complex 01 targets the arteries and the heart.17 Chronic systemic infection often leads to endothelial dysfunction and impaired microcirculation, which can restrict the delivery of oxygen and therapeutic peptides to the brain's reward centers.6 By restoring the elasticity of the vascular walls and reducing inflammation within the vessel lining, PC 01 ensures that the neurotrophic peptides in PC 021 can reach their target tissues efficiently.7

### **Peptide Complex 08 and 16: The Metabolic and Gut-Brain Axis**

Anhedonia cannot be fully resolved without addressing the systemic "inflammatory load" and the primary sites of immune activation. Peptide Complex 08 targets the liver, which is the body's primary site for clearing inflammatory cytokines and acute-phase proteins.13 Supporting hepatic function helps reduce the overall burden of toxins on the central nervous system.7

Peptide Complex 16 targets the stomach and duodenum.17 Given that roughly 70% of the immune system is housed in the gut, any chronic infection often involves gastrointestinal dysbiosis or "leaky gut," which serves as a perpetual source of systemic inflammation.7 Using PC 16 to repair the intestinal lining and modulate gut-associated lymphoid tissue (GALT) is a critical secondary strategy for stopping the "cytokine rain" that poisons the brain's dopamine circuits.7

### **Overview of Secondary Peptide Complexes**

While the primary treatment focus rests on the immune and nervous systems, the other complexes in the 01-19 series provide supportive roles that address the systemic complications of chronic infection.

| Complex ID | Target Organ / System | Potential Role in Anhedonia Recovery |
| :---- | :---- | :---- |
| PC 04 / 05 | Spine, Joints, and Bones | Reduces chronic pain stressors that deplete DA 17 |
| PC 06 | Thyroid Gland | Optimizes metabolic rate and DA receptor sensitivity 17 |
| PC 07 | Pancreas | Manages insulin resistance, which is linked to inflammation 17 |
| PC 11 / 15 | Urinary / Kidneys | Facilitates excretion of metabolic and viral waste 17 |
| PC 12 | Respiratory System | Resolves pulmonary infections contributing to systemic load 17 |
| PC 14 | Venous System | Improves waste removal and reduces neurovascular congestion 17 |
| PC 17 / 18 | Eyes and Ears | Restores sensory integration often dulled by anhedonia 17 |
| PC 19 | Weather Sensitivity / Cardio | Stabilizes autonomic response to environmental stressors 17 |

## **Synergistic Integration: The Optimal Therapeutic Protocol**

The evidence suggests that the "best" treatment for chronic infection-induced anhedonia is not a single peptide but a phased combination that addresses the immune-dopamine axis from multiple angles. A single-target approach is likely to fail because the inflammation will continue to suppress any newly synthesized dopamine, and the repair of the nervous system cannot occur while the infection remains unresolved.

### **Phase One: Immune Resolution and Detoxification**

The initial focus must be the removal of the pro-inflammatory stimulus. Utilizing Peptide Complex 03 (Immune) and Peptide Complex 08 (Liver) serves to activate the body's natural defense mechanisms and clear the existing inflammatory markers from the bloodstream.7 During this phase, the reduction of ![][image3] and ![][image2] levels begins to lift the "sickness behavior" profile, allowing the brain to begin its shift toward recovery.1

### **Phase Two: Neurological Repair and Circulation**

Once the systemic inflammatory load is reduced, the second phase should introduce Peptide Complex 021 (Nervous System) and Peptide Complex 01 (Arteries).15 This combination provides the epigenetic signals required for neuronal repair and ensure that the neurovascular unit is capable of supporting the metabolic demands of newly restored reward signaling.7 PC 021 directly addresses the anhedonic state by promoting the synthesis of proteins involved in dopamine synthesis (![][image4] regeneration) and receptor expression.1

### **Phase Three: Systems Stabilization**

The final phase incorporates complexes like PC 06 (Thyroid) and PC 19 (Adaptability) to normalize the endocrine environment and stabilize the autonomic nervous system.7 Chronic infection often leaves the hypothalamic-pituitary-adrenal (HPA) axis in a state of dysregulation, which can cause relapse if not addressed.7 By resetting the circadian rhythms and metabolic baseline, these complexes ensure the long-term maintenance of the "healthy phenotype".7

## **Insights into the Epigenetic Reset and the Kynurenine Pathway**

A critical second-order insight into this treatment protocol is the restoration of the "Tryptophan Switch." In the presence of chronic inflammation, the body’s metabolic pathways are diverted toward the production of kynurenine metabolites instead of serotonin and melatonin.2 By using PC 03 and PC 08 to dampen the inflammatory fire, the clinician effectively "flips the switch" back to serotonin production.2 This has a cascade of positive effects: increased serotonin levels improve mood and resilience, while increased melatonin levels from the restored pineal function provide the antioxidant protection necessary for the brain to heal during sleep.8

Furthermore, the third-order implications of using these bioregulators involve a profound phenotypic shift. Chronic illness often induces a "disease phenotype"—a state where the organism's genetic expression is locked into a pattern of inflammation, energy conservation, and social withdrawal.4 Peptide bioregulators, through their site-specific interaction with DNA and histones, act as molecular "resets" that can transition a patient back to a "healthy phenotype".7 This suggests that the anhedonia observed in chronic infection is not a permanent damage to the brain but a reversible epigenetic state that can be corrected by providing the body with the appropriate short-chain peptide signals.7

## **Comparative Analysis of Targeted Peptides for Mental Resilience**

While the RuPharma liquid complexes provide a broad-spectrum approach, comparing their active components to other well-known peptides helps contextualize their efficacy for anhedonia.

| Therapy Type | Leading Candidate | Primary Mechanism | Advantage for Anhedonia |
| :---- | :---- | :---- | :---- |
| Bioregulator | Cerluten (PC 021\) | Brain-specific protein synthesis 15 | Direct repair of reward centers |
| Immunomodulator | Thymalin (PC 03\) | Cytokine / T-cell regulation 13 | Removal of inflammatory DA inhibitors |
| Mood Enhancer | Selank | Anti-anxiety / Mood balance 22 | Rapid relief from stress/irritability |
| Energy Booster | NAD+ | Mitochondrial repair 23 | Addresses physical fatigue |
| Healing Peptide | BPC-157 | Gut-brain axis repair 18 | Reduces systemic source of inflammation |

Cerluten (PC 021\) stands out as the most targeted for the neurological seat of anhedonia, while Thymalin (PC 03\) is the most targeted for the infectious root. The synergy between these two is the defining characteristic of an expert-level peptide protocol.7

## **The Role of HLA Alleles and Viral Antigenicity in Treatment Response**

A nuanced understanding of the patient's individual genetic makeup also plays a role in the effectiveness of peptide therapy. Research indicates that certain peptides show a marked interaction with HLA (Human Leukocyte Antigen) class I alleles, which in turn activate natural killer (NK) cells to fight infection.24 Interestingly, individuals with specific HLA alleles (such as ![][image5]) may have an increased susceptibility to chronic inflammatory conditions, making them more prone to infection-induced anhedonia.25 For these "high-sensitivity" patients, the use of thymic bioregulators like PC 03 is even more critical, as their innate immune system may require the specific "re-training" that these peptides provide to successfully clear the pathogen and resolve the anhedonic state.7

The ability of these peptides to stimulate a targeted immune response against viral antigens—without inducing a full-blown cytokine storm—is a key clinical advantage.13 In studies of SARS-CoV-2 and other viral infections, peptide cocktails targeting various stages of viral invasion have shown synergistic inhibition, suggesting that the broad approach of the PC series (01–19) may provide a more comprehensive defense than any single-agent treatment.13

## **Clinical Evidence of Systemic Restoration**

Data from long-term clinical studies (6–12 years) demonstrate that the consistent application of thymic and pineal bioregulators (which form the foundation of PC 03 and PC 021/PC 19\) leads to significant improvements in health markers and a decrease in mortality rates.9 For instance, patients treated with a combination of Thymalin and Epithalamin showed a 2.5-fold decrease in mortality compared to control groups, and a 4.1-fold decrease when treated annually for six years.9 This long-term data correlates with the stabilization of cellular function and the activation of DNA repair genes (such as those involved in Nucleotide Excision Repair and Base Excision Repair), which are essential for recovering from the genomic stress imposed by chronic infections.9

In the context of the oral cavity—often a reservoir for chronic low-grade infection—polypeptide drugs have been proven to reduce markers of inflammation such as C-reactive protein (![][image6]) and ![][image7] while increasing levels of protective albumin and calcium.27 This demonstrates the capacity of these peptides to normalize systemic metabolism and restore the body's local resistance to pathogens, which is a necessary precursor to resolving the behavioral symptoms of sickness and anhedonia.27

## **Final Synthesis and Recommendation**

To determine the "best" treatment for chronic infections inducing anhedonia among the RuPharma liquid complexes, one must prioritize the complexes that address the etiological source (inflammation) and the clinical manifestation (dopamine dysfunction).

1. **Peptide Complex 03 (Immune System)** is the most critical intervention for the root cause. It provides the necessary thymic bioregulation to resolve the chronic infectious state and suppress the overproduction of pro-inflammatory cytokines that sabotage the reward system.7  
2. **Peptide Complex 021 (Nervous System)** is the most critical intervention for the neurological restoration of pleasure and motivation. It directly targets the cerebral cortex and subcortical structures to repair the dopaminergic pathways that have been functionally silenced by chronic inflammation.1  
3. **Peptide Complex 08 (Liver)** and **Peptide Complex 16 (Stomach/Duodenum)** are the best supporting agents. They address the gut-brain axis and the body's detoxification capacity, ensuring that the "inflammatory load" is cleared and that the source of systemic cytokines is minimized.7

While any of the provided complexes could play a role in a broad wellness strategy, the combination of **PC 03** and **PC 021** represents the most scientifically robust approach to treating the specific condition of infection-induced anhedonia. This dual-action protocol addresses the immune-dopamine axis with a level of precision that conventional antidepressants or antibiotics cannot achieve, offering the possibility of a true epigenetic reset and a return to a healthy, reward-sensitive state.7

Furthermore, the integration of **PC 01 (Arteries)** ensures that these restorative signals are successfully delivered to the CNS, while **PC 19 (Adaptability)** provides the final stabilizing layer for the patient's autonomic and cardiovascular resilience.7 By applying these bioregulators as a cohesive system, the patient can transition from the "disease phenotype" of chronic illness and apathy to a "healthy phenotype" characterized by vitality, mental clarity, and the full capacity for hedonic experience.7

#### **Works cited**

1. Cytokine Effects on the Basal Ganglia and Dopamine Function: the Subcortical Source of Inflammatory Malaise \- PMC, accessed January 25, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3484236/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3484236/)  
2. Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications \- PMC \- PubMed Central, accessed January 25, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11060479/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11060479/)  
3. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise \- PubMed, accessed January 25, 2026, [https://pubmed.ncbi.nlm.nih.gov/23000204/](https://pubmed.ncbi.nlm.nih.gov/23000204/)  
4. Inflammation Effects on Motivation and Motor Activity: Role of Dopamine \- ResearchGate, accessed January 25, 2026, [https://www.researchgate.net/publication/305792101\_Inflammation\_Effects\_on\_Motivation\_and\_Motor\_Activity\_Role\_of\_Dopamine](https://www.researchgate.net/publication/305792101_Inflammation_Effects_on_Motivation_and_Motor_Activity_Role_of_Dopamine)  
5. Vladimir Khavinson \- Wikipedia, accessed January 25, 2026, [https://en.wikipedia.org/wiki/Vladimir\_Khavinson](https://en.wikipedia.org/wiki/Vladimir_Khavinson)  
6. Peptide medicines: past, present, future | Khavinson \- Клиническая медицина, accessed January 25, 2026, [https://www.clinmedjournal.com/jour/article/view/29/0?locale=en\_US](https://www.clinmedjournal.com/jour/article/view/29/0?locale=en_US)  
7. Bioregulators: A Revolutionary Approach to Complex Chronic Illness, accessed January 25, 2026, [https://gordonmedical.com/bioregulators-a-revolutionary-approach-to-complex-chronic-illness/](https://gordonmedical.com/bioregulators-a-revolutionary-approach-to-complex-chronic-illness/)  
8. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism \- MDPI, accessed January 25, 2026, [https://www.mdpi.com/1420-3049/25/3/609](https://www.mdpi.com/1420-3049/25/3/609)  
9. Peptide Bioregulator Protocol \- Age Management Medicine Group, accessed January 25, 2026, [https://agemed.org/wp-content/uploads/LAWRENCE-Peptide-Bioregulator-Clinical-Study.pdf](https://agemed.org/wp-content/uploads/LAWRENCE-Peptide-Bioregulator-Clinical-Study.pdf)  
10. Anhedonia and Inflammation: Hiding in Plain Sight | American Journal of Psychiatry, accessed January 25, 2026, [https://psychiatryonline.org/doi/10.1176/appi.ajp.20250261](https://psychiatryonline.org/doi/10.1176/appi.ajp.20250261)  
11. Peptide Bio-regulators for Healthy Aging | Mill Valley, Marin County, CA, accessed January 25, 2026, [http://www.drlisabrent.com/blog/2022/7/31/peptide-bio-regulators-for-healthy-aging](http://www.drlisabrent.com/blog/2022/7/31/peptide-bio-regulators-for-healthy-aging)  
12. Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties, accessed January 25, 2026, [https://www.mdpi.com/1422-0067/26/6/2691](https://www.mdpi.com/1422-0067/26/6/2691)  
13. Vladimir KHAVINSON | Professor, M.D., Ph.D. | Peptide department | Research profile, accessed January 25, 2026, [https://www.researchgate.net/profile/Vladimir-Khavinson](https://www.researchgate.net/profile/Vladimir-Khavinson)  
14. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line \- PMC \- PubMed Central, accessed January 25, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/)  
15. A-5 Cerluten Original Natural Khavinson Brain Peptide Bioregulator 60 capsules | eBay, accessed January 25, 2026, [https://www.ebay.com/itm/146844876289](https://www.ebay.com/itm/146844876289)  
16. Peptide bioregulation of aging: results and prospects \- PubMed, accessed January 25, 2026, [https://pubmed.ncbi.nlm.nih.gov/19830585/](https://pubmed.ncbi.nlm.nih.gov/19830585/)  
17. Perplexed by Peptides? | MindMeister Mind map, accessed January 25, 2026, [https://www.mindmeister.com/1043569289/perplexed-by-peptides](https://www.mindmeister.com/1043569289/perplexed-by-peptides)  
18. How Clinical Peptide Therapy Can Support Immune System Health \- Apex Integrative Medicine, accessed January 25, 2026, [https://apexintegrativemed.com/boost-immunity-with-clinical-peptide-therapy/](https://apexintegrativemed.com/boost-immunity-with-clinical-peptide-therapy/)  
19. Peptide Therapy: 5 Best Peptide Restorative Treatments of 2025, accessed January 25, 2026, [https://www.thrivehormonalhealth.com/what-is-peptide-therapy/](https://www.thrivehormonalhealth.com/what-is-peptide-therapy/)  
20. Peptides | Therapeutic Health, accessed January 25, 2026, [https://www.therapeutic-health.com/our-services/functional-medicine/peptides/](https://www.therapeutic-health.com/our-services/functional-medicine/peptides/)  
21. Peptide medicines: past, present, future | Khavinson \- Клиническая медицина, accessed January 25, 2026, [https://www.clinmedjournal.com/jour/article/view/29?locale=en\_US](https://www.clinmedjournal.com/jour/article/view/29?locale=en_US)  
22. Poor Mood | Neem Medical Spa, accessed January 25, 2026, [https://neemmedicalspa.com/concerns/wellness/poor-mood/](https://neemmedicalspa.com/concerns/wellness/poor-mood/)  
23. How Peptide Therapy Support for Brain Fog & Anxiety Relief? \- Viva Medspa, accessed January 25, 2026, [https://vivamedspa.life/how-to-reduce-brain-fog-with-peptide-therapy/](https://vivamedspa.life/how-to-reduce-brain-fog-with-peptide-therapy/)  
24. Conserved HLA binding peptides from five non-structural proteins of SARS-CoV-2—An in silico glance \- PubMed Central, accessed January 25, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7425717/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7425717/)  
25. 4aen \- Proteopedia, life in 3D, accessed January 25, 2026, [https://proteopedia.org/wiki/index.php/4aen](https://proteopedia.org/wiki/index.php/4aen)  
26. Synergistic peptide combinations designed to suppress SARS-CoV-2 \- PMC \- NIH, accessed January 25, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11079089/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11079089/)  
27. The effectiveness of the use of polypeptide drugs and their effect on the metabolic parameters of oral fluid in patients with generalized periodontitis in depending on blood type \- Pharmacia, accessed January 25, 2026, [https://pharmacia.pensoft.net/article/82421/](https://pharmacia.pensoft.net/article/82421/)

[image1]: <data:image/png;base64,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>

[image2]: <data:image/png;base64,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>

[image3]: <data:image/png;base64,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>

[image4]: <data:image/png;base64,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>

[image5]: <data:image/png;base64,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>

[image6]: <data:image/png;base64,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>

[image7]: <data:image/png;base64,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>